相关实验视频
Updated: Jun 14, 2025

08:29
Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
Published on: May 14, 2018
9.9K
长非编码RNAs在发展抗帕克利塔塞尔三阴性乳腺癌中的作用:系统性审查
Davood Dalil1, Saeid Iranzadeh1, Alireza Barouh2
1Faculty of Medicine, Shahed University, Tehran, Iran.
Cancer treatment and research communications
|May 9, 2025
概括
长非编码RNAs (lncRNAs) 在三阴性乳腺癌 (TNBC) 中显著影响包素 (PTX) 耐药性. 了解 lncRNA 作用为改善 TNBC 患者化疗疗效率提供了新的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 长非编码RNAs (lncRNAs) 越来越多地被认为是它们在癌症化学抵抗中的作用.
- 帕克利塔克塞尔 (PTX) 耐药性是治疗三阴性乳腺癌 (TNBC) 的一个主要挑战.
研究的目的:
- 系统地审查lncRNAs在三阴性乳腺癌 (TNBC) 中的帕克利塔塞尔 (PTX) 耐药性的作用.
- 总结潜在的lncRNA标和参与TNBC中PTX耐药性的机制.
主要方法:
- 在PubMed,Scopus和Web of Science数据库中进行系统的文献搜索,直到2023年11月.
- 包含/排除标准适用于最初确定的95篇出版物,导致19篇包含的文章.
- 使用维尔茨堡方法质量评分 (W-MeQS) 进行包含研究的质量评估.
主要成果:
- 包括19项研究,研究PTX耐药TNBC中的lncRNA.
- 发现关键的 lncRNAs 调节细胞周期,细胞亡,上皮细胞转变为介质细胞,自和血管生成.
- 这些机制调解TNBC细胞对PTX的抗性.
结论:
- lncRNAs在促进或抑制TNBC中PTX耐药性方面发挥着重要作用.
- 在抗PTX的TNBC中,上调或下调的lncRNAs代表了潜在的治疗点.
- 向lncRNAs可能会提高TNBC化疗的疗效.
相关概念视频
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
piRNA - Piwi-interacting RNAs
6.8K
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
6.8K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K

